title: Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria.
abstract: OBJECTIVE
  This study presents the two-year clinical outcomes of the Amsterdam ABSORB registry stratified by lesion and patient characteristics complexity (SYNTAX score and ABSORB II study enrolment criteria).
  
  
  RESULTS
  Patients treated with BVS were included in this prospective registry and stratified according to the ABSORB II trial inclusion and exclusion criteria and the SYNTAX score. The registry comprises 135 patients (59±11 years, 73% male, 18% diabetic) with 159 lesions. Median follow-up duration was 774 days (742-829). Median SYNTAX score was 11.5 (Q1-Q3: 6-17.5). Two-year event rates were cardiac death 0.7%, MI 5.3%, TVR 13.6%, TLR 11.4%, definite ST 3.0% and TVF 14.4%, respectively. Stratified analyses showed a significantly higher revascularisation rate in patients not meeting ABSORB II criteria (TVR: 2.3% vs. 19.2%, p=0.010, and TLR: 2.3% vs. 15.8%, p=0.025) and patients with SYNTAX score ≥11.5 (TVR: 4.8% vs. 21.8%, p=0.006, and TLR: 3.2% vs. 17.4%, p=0.007).
  
  
  CONCLUSIONS
  The use of Absorb BVS in patients meeting the ABSORB II trial inclusion criteria or those with low SYNTAX scores is associated with acceptable clinical outcomes at two-year follow-up. Patients with more complex characteristics have significantly higher revascularisation rates.
authors: AMC Heartcenter, Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands.
authors: Robin P
authors: RP
authors: Kraak
authors: Maik J
authors: MJ
authors: Grundeken
authors: Mariëlla E
authors: ME
authors: Hassell
authors: Joëlle
authors: J
authors: Elias
authors: Karel T
authors: KT
authors: Koch
authors: José P
authors: JP
authors: Henriques
authors: Jan J
authors: JJ
authors: Piek
authors: Jan
authors: J
authors: Baan
authors: Marije M
authors: MM
authors: Vis
authors: Jan G P
authors: JG
authors: Tijssen
authors: Robbert J
authors: RJ
authors: de Winter
authors: Joanna J
authors: JJ
authors: Wykrzykowska
mesh_terms: D020341:Absorbable Implants / Q000009:adverse effects; D000328:Adult; D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D017023:Coronary Angiography / Q000379:methods; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000628:therapy; D062645:Percutaneous Coronary Intervention / Q000379:methods; D011474:Prosthesis Design; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D020123:Sirolimus